This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shaddy, R. E. Articles by Fuller, T. C. Search for Related Content PubMed PubMed Citation Articles by Shaddy, R. E. Articles by Fuller, T. C.

(Circulation. 1996;94:1063-1067.)
© 1996 American Heart Association, Inc.

Articles

Prospective Analysis of HLA Immunogenicity of Cryopreserved Valved Allografts Used in Pediatric Heart Surgery

Robert E. Shaddy, MD; Dixie D. Hunter, RN; Karen A. Osborn, RN; Linda M. Lambert, BS; L. LuAnn Minich, MD; John A. Hawkins, MD; Edwin C. McGough, MD; Thomas C. Fuller, PhD

the Departments of Pediatrics (R.E.S., D.D.H., K.A.O., L.L.M.), Surgery (L.M.L., J.A.H., E.C.M.), and Pathology (T.C.F.), University of Utah School of Medicine and Primary Children's Medical Center (Salt Lake City).

Correspondence to Robert E. Shaddy, MD, Division of Cardiology, Primary Children's Medical Center, 100 N Medical Dr, Salt Lake City, UT 84113. E-mail shaddy@med.utah.edu.

Background The HLA immunogenicity of cryopreserved valved allografts used in the surgical repair of congenital heart defects is unknown.

Methods and Results To determine the immunogenicity of these allografts, we measured prospectively the frequency of panel-reactive HLA class I alloantibodies (PRA) before, 1 month after, and 3 months after allograft implantation in 9 children (age, 5.4±2.1 years) and after open-heart surgery without allograft implantation in 11 age-matched control children (age, 4.0±1.5 years). PRA was determined against an HLA-select frozen T-lymphocyte panel using the antiglobulin cytotoxicity technique. After allograft implantation, PRA increased from 3.2±2.7% before surgery to 63.3±12% at 25±2 days after surgery and 99.7±0.3% at 3.4±0.3 months after surgery. The use of dithiothreitol to remove IgM alloantibodies resulted in a modest decrease in PRA at 1 month (33.2±13%) but no change at 3 months (93.0±3.4%), suggesting the initial humoral response is an IgM alloantibody that switches almost exclusively to IgG by 3 months. Control patients showed no increase in PRA over time: 1.6±1% before surgery, 3.2±1% at 28±5 days after surgery, and 1.7±1% at 2.7±0.3 months after surgery.

Conclusions Cryopreserved valved allografts in children induce a marked HLA alloantibody response that increases to broad panel reactivity within 3 months after surgery. This HLA sensitization has potential not only for causing deleterious effects on allograft function but also for limiting the future opportunity of heart transplantation in patients who receive cryopreserved valved allografts.

Key Words: heart defects, congenital • immune system • pediatrics • valves

This article has been cited by other articles:

				T. Konuma, E. J. Devaney, E. L. Bove, S. Gelehrter, J. C. Hirsch, Z. Tavakkol, and R. G. Ohye Performance of CryoValve SG decellularized pulmonary allografts compared with standard cryopreserved allografts. Ann. Thorac. Surg., September 1, 2009; 88(3): 849 - 854. [Abstract] [Full Text] [PDF]

				B. Feingold, P. D. Wearden, V. O. Morell, D. Galvis, and C. Galambos Expression of A and B Blood Group Antigens on Cryopreserved Homografts Ann. Thorac. Surg., January 1, 2009; 87(1): 211 - 214. [Abstract] [Full Text] [PDF]

				C. R. Hampton and E. D. Verrier Stentless Aortic Valve Replacement: Autograft/Homograft Card. Surg. Adult, January 1, 2008; 3(2008): 895 - 914. [Full Text]

				C. Mavroudis, B. J. Deal, C. L. Backer, R. D. Stewart, W. H. Franklin, S. Tsao, K. M. Ward, and R. A. DeFreitas 111 Fontan Conversions with Arrhythmia Surgery: Surgical Lessons and Outcomes Ann. Thorac. Surg., November 1, 2007; 84(5): 1457 - 1466. [Abstract] [Full Text] [PDF]

				Z. Tavakkol, S. Gelehrter, C. S. Goldberg, E. L. Bove, E. J. Devaney, and R. G. Ohye Superior Durability of Synergraft Pulmonary Allografts Compared With Standard Cryopreserved Allografts Ann. Thorac. Surg., November 1, 2005; 80(5): 1610 - 1614. [Abstract] [Full Text] [PDF]

				J. W. Brown, M. Ruzmetov, M. D. Rodefeld, P. Vijay, and M. W. Turrentine Right Ventricular Outflow Tract Reconstruction With an Allograft Conduit in Non-Ross Patients: Risk Factors for Allograft Dysfunction and Failure Ann. Thorac. Surg., August 1, 2005; 80(2): 655 - 664. [Abstract] [Full Text] [PDF]

				D. K. Hooper, J. A. Hawkins, T. C. Fuller, T. Profaizer, and R. E. Shaddy Panel-Reactive Antibodies Late After Allograft Implantation in Children Ann. Thorac. Surg., February 1, 2005; 79(2): 641 - 644. [Abstract] [Full Text] [PDF]

				A. Ketchedjian, P. Kreuger, H. Lukoff, E. Robinson, A. Linthurst-Jones, K. Crouch, L. Wolfinbarger, and R. Hopkins Ovine panel reactive antibody assay of HLA responsivity to allograft bioengineered vascular scaffolds J. Thorac. Cardiovasc. Surg., January 1, 2005; 129(1): 159 - 166. [Abstract] [Full Text] [PDF]

				R. E. Shaddy, T. C. Fuller, J. B. Anderson, L. M. Lambert, M. K. Brinkman, T. Profaizer, and J. A. Hawkins Mycophenolic mofetil reduces the HLA antibody response of children to valved allograft implantation Ann. Thorac. Surg., May 1, 2004; 77(5): 1734 - 1739. [Abstract] [Full Text] [PDF]

				M. Wojtalik, W. Mrowczynski, J. Zeromski, and R. Bartkowski Does contegra xenograft implantation evoke cellular immunity in children? Interactive CardioVascular and Thoracic Surgery, September 1, 2003; 2(3): 273 - 278. [Abstract] [Full Text] [PDF]

				J. A. Hawkins, N. D. Hillman, L. M. Lambert, J. Jones, G. B. Di Russo, T. Profaizer, T. C. Fuller, L. L. Minich, R. V. Williams, and R. E. Shaddy Immunogenicity of decellularized cryopreserved allografts in pediatric cardiac surgery: comparison with standard cryopreserved allografts J. Thorac. Cardiovasc. Surg., July 1, 2003; 126(1): 247 - 252. [Abstract] [Full Text] [PDF]

				C. R. Hampton, A. J. Chong, and E. D. Verrier Stentless Aortic Valve Replacement: Homograft/Autograft Card. Surg. Adult, January 1, 2003; 2(2003): 867 - 888. [Full Text]

				R. E. Shaddy and J. A. Hawkins Immunology and failure of valved allografts in children Ann. Thorac. Surg., October 1, 2002; 74(4): 1271 - 1275. [Abstract] [Full Text] [PDF]

				W. J. Wells, H. Arroyo Jr, R. M. Bremner, J. Wood, and V. A. Starnes Homograft conduit failure in infants is not due to somatic outgrowth J. Thorac. Cardiovasc. Surg., July 1, 2002; 124(1): 88 - 96. [Abstract] [Full Text] [PDF]

				R. E. Shaddy, L. M. Lambert, T. C. Fuller, T. Profaizer, D. D. Thompson, S. I. Baker, K. A. Osborne, and J. A. Hawkins Prospective randomized trial of azathioprine in cryopreserved valved allografts in children Ann. Thorac. Surg., January 1, 2001; 71(1): 43 - 47. [Abstract] [Full Text] [PDF]

				J. A. Hawkins, J. P. Breinholt, L. M. Lambert, T. C. Fuller, T. Profaizer, E. C. McGough, and R. E. Shaddy CLASS I AND CLASS II ANTI-HLA ANTIBODIES AFTER IMPLANTATION OF CRYOPRESERVED ALLOGRAFT MATERIAL IN PEDIATRIC PATIENTS J. Thorac. Cardiovasc. Surg., February 1, 2000; 119(2): 324 - 330. [Abstract] [Full Text] [PDF]